Abstract
Organ procurement in the US has received attention from government officials and policymakers the last two years, culminating in CMS releasing an updated Final Rule related to organ donation this year. This regulatory change revises how organ procurement organizations (OPOs), the federal contractors tasked with managing deceased donation, are evaluated and certified/de-certified. We used 2019 data and the CMS methodology to calculate race-stratified donation data among racial/ethnic minorities across the 57 OPOs. We found that the variability in donation rates across the 57 OPOs are greater among minority populations than non-Hispanic white potential donors. Among Tier 3 OPOs, there are: a) some with low donation rates across all racial/ethnic groups; b) some with low donation rates among only certain groups, and c) some where donation rates are lowest among non-Hispanic white patients. Among low-performing OPOs, these race/ethnicity-stratified data show that under-performance in certain areas is not due to the population demographics, and identifies areas for targeted interventions to increase donation and avoid decertification
Competing Interest Statement
Ms. Doby and Dr. Lynch have received research support from the Mid-America Transplant Foundation. Positive Rhetoric LLC has provided paid consultation services to the Arkansas Regional Organ Recovery Agency and Life Connection of Ohio.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Organ Procurement and Transplantation Network (OPTN) at https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/ and National Center for Health Statistics Multiple Cause of Death data at https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The supplementary table was updated to remove data for UTOP for Asian and and non-Hispanic Black donation rates as on re-review of the data it was noted that there were <25 CALC deaths in that OPO. The maps did not need to be updated as UTOP was listed as "missing data" for donation rates for non-Hispanic Black patients.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
